Royal Bank Of Canada Cognition Therapeutics Inc Transaction History

Royal Bank Of Canada

$458 Billion
Q1 2025

A detailed history of Royal Bank Of Canada transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 400 shares of CGTX stock, worth $136. This represents 0.0% of its overall portfolio holdings.

Number of Shares

400

Holding current value

$136

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.39 - $0.85 $156 - $340	400 New	400 $0
Q2 2024 Aug 14, 2024	BUY	$1.66 - $2.62 $554 - $875	334 Added 8350.0%	338 $0
Q1 2024 Nov 05, 2024	SELL	$1.78 - $2.53 $594 - $845	-334 Reduced 98.82%	4 $0
Q1 2024 May 15, 2024	SELL	$1.78 - $2.53 $347 - $493	-195 Reduced 97.99%	4 $0
Q4 2023 Feb 14, 2024	BUY	$0.96 - $2.42 $168 - $425	176 Added 765.22%	199 $0
Q3 2023 Nov 14, 2023	SELL	$1.25 - $1.9 $288 - $438	-231 Reduced 90.94%	23 $0
Q2 2023 Aug 14, 2023	BUY	$1.56 - $3.38 $396 - $858	254 New	254 $0
Q4 2022 Feb 14, 2023	BUY	$1.17 - $3.51 $336 - $1,010	288 Added 257.14%	400 $0
Q3 2022 Nov 14, 2022	BUY	$1.63 - $3.6 $182 - $403	112 New	112 $0
Q1 2022 May 16, 2022	SELL	$2.41 - $6.9 $241 - $690	-100 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.1 - $12.98 $509 - $1,298	100 New	100 $1,000

Others Institutions Holding CGTX

# of Institutions

Shares Held

14M

Call Options Held

Put Options Held

Bios Capital Management, LP Fort Worth, TX

6M
Shares

$2.04 Million
3.19% of portfolio
Pathstone Family Office, LLC Englewood, NJ

2.21M
Shares

$749,828
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

1.24M
Shares

$421,316
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

1.01M
Shares

$342,579
0.0% of portfolio
Sigma Planning Corp Ann Arbor, MI

608K
Shares

$206,852
0.01% of portfolio

View Full List

About COGNITION THERAPEUTICS INC

Ticker CGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,710,700
Market Cap $7.72M
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...

More about CGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account